• Skip to primary navigation
  • Skip to main content
  • Skip to footer

HepVu

HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

  • INTERACTIVE MAP
  • Location Profiles
  • Find Services
  • News & Updates
  • Events
  • Tools & Resources
Home Vu Q&A Page 2

Vu Q&A

December 20, 2023

Frank Hood on Hepatitis B and the Importance of Viral Hepatitis Surveillance

November 1, 2023

HepVu and NASTAD on the Viral Hepatitis Surveillance Status Report and New Trends

Read More

September 19, 2023

Dr. Jagpreet Chhatwal on the White House’s Plan to Eliminate Hepatitis C

Read More

August 8, 2023

Dr. Samuel So on Global Hepatitis B Elimination Efforts

Read More

August 8, 2023

Diana Padilla on the Intersection of Opioids and Hepatitis C

Read More

August 8, 2023

Tessa Bialek and Dr. Matthew J. Akiyama on Expanding Hepatitis C Testing and Treatment in Prisons and Jails

Read More

April 13, 2023

Developing a Continuum of Care (Care Cascade) for Hepatitis C

Read More

November 16, 2022

Suzanne Davies on Managed Care Organizations and Medicaid

Read More

October 27, 2022

Dr. Mark Sulkowski on Relationship Between Viral Hepatitis, HIV & Liver Cancers

Read More

October 24, 2022

Dr. Heather Bradley and Boatemaa Ntiri-Reid on the Inaugural Viral Hepatitis Surveillance Report

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5

Sign up for HepVu updates.

Footer

AIDSVu HepVu

HepVu is presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc.

  • About
  • FAQ
  • Data Methods
  • Datasets

Questions?
Info@HepVu.org

Media Inquiries
(202) 854-0480
Media@HepVu.org

Follow Us

  • Facebook
  • Twitter

© 2025 HepVu. All Rights Reserved.

  • Privacy Policy
  • Contact Us

Get HepVu in Your Inbox

Sign up to stay informed on new data, maps, expert Q&As, and infographics about Hepatitis C and opioids where you live.